BioCryst to Present at Upcoming Investor Conferences
Rhea-AI Summary
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced its participation in three upcoming investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5 at 1:30 p.m. ET, the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9 at 9:00 a.m. ET, and the 2024 Cantor Global Healthcare Conference in New York on September 19 at 12:45 p.m. ET.
Investors and interested parties can access live audio webcasts and replays of the presentations through the Investors & Media section of BioCryst's website at http://www.biocryst.com. This series of presentations provides an opportunity for BioCryst to showcase its progress and engage with the investment community.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BCRX declined 1.00%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
- 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 p.m. ET.
- H.C. Wainwright 26th Annual Global Investment Conference in New York on Monday, September 9, 2024, at 9:00 a.m. ET.
- 2024 Cantor Global Healthcare Conference in New York on Thursday, September 19, 2024, at 12:45 p.m. ET.
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
When and where is BioCryst (BCRX) presenting at the Wells Fargo Healthcare Conference in 2024?
What time is BioCryst's (BCRX) presentation at the H.C. Wainwright Global Investment Conference in 2024?
Where can investors access the webcasts of BioCryst's (BCRX) investor conference presentations?
What is the date and time of BioCryst's (BCRX) presentation at the 2024 Cantor Global Healthcare Conference?
